Portal de Periódicos da CAPES

Diabetic Cardiomyopathy

2006; Lippincott Williams & Wilkins; Volume: 99; Issue: 1 Linguagem: Inglês

10.1161/01.res.0000233141.65522.3e

1524-4571

Elisa Messina, Alessandro Giacomello,

Adipose Tissue and Metabolism

HomeCirculation ResearchVol. 99, No. 1Diabetic Cardiomyopathy Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBDiabetic CardiomyopathyA "Cardiac Stem Cell Disease" Involving p66Shc, an Attractive Novel Molecular Target for Heart Failure Therapy Elisa Messina and Alessandro Giacomello Elisa MessinaElisa Messina From the Department of Experimental Medicine and Pathology, University of Rome "La Sapienza", Rome, Italy. and Alessandro GiacomelloAlessandro Giacomello From the Department of Experimental Medicine and Pathology, University of Rome "La Sapienza", Rome, Italy. Originally published7 Jul 2006https://doi.org/10.1161/01.RES.0000233141.65522.3eCirculation Research. 2006;99:1–2Diabetes, as well as hypertension and aging, have similar effects on heart dysfunction, resulting in left ventricular hypertrophy and stiffness. These three pathological states share two common points of no return: oxidative stress and ROS formation.Research in this area is not new. For the past 30 to 40 years, basic and pharmacological research has focused on efforts to block the production or counteract the effects of these highly reactive, unstable molecules. It is only in the last few years that, their direct toxic role in cellular structures notwithstanding, ROS has been regarded as a second messenger.1 This represents a more subtle and insidious mechanism of action, because their byproduct and amplified effects may depend on activated cascades leading to persistent consequences (apoptosis, necrosis), even if ROS are naturally or pharmacologically contrasted.In this regard the adaptor protein p66Shc, which along with p46Shc and p52Shc, is encoded by the ShcA gene, has been demonstrated to be a target of ROS.2 p46Shc and p52Shc are ubiquitous isoforms, derived from the same mRNA through alternative start sites.3 In contrast, p66Shc expression is restricted to certain cell types and stimulatory conditions through epigenetic modifications of its distinct promoter.4–5 Shc is tyrosine-phosphorylated in response to growth factors and Ang II.2–6 Once phosphorylated, Shc forms a complex with Grb2, recruiting the Son-of-sevenless (SOS) exchange protein to the plasma membrane for activation of Ras. The three Shc isoforms have distinct physiological roles. In particular, whereas both p46Shc and p52Shc promote cellular proliferation and differentiation via Ras and MAP kinases, p66Shc inhibits Ras/ERK signaling and blunts mitogenic responses, at least in part by competing with p52Shc for a limited pool of Grb2. Furthermore, p66Shc sensitizes cells to apoptosis in response to oxidative stress through a mechanism that involves a phosphorylation event at S36.7 The phosphorylation-induced repression of Forkhead transcription factors (which regulate the expression of several antioxidant enzymes), and the activation of p66 mitochondrial pool (leading the induction of mPTP opening and cytochrome C release), represent the main pathways involved in the contribution of this protein to the cellular sensitization to ROS-induced apoptosis.8,9 p66Shc knockout mice have shown an increased resistance to oxidative stress, a 30% increase in life span, and a resistance to the deleterious remodeling effects of a subpressor dose of Ang II.2 Therefore the ROS formation scenario in heart failure has been enriched by a new molecular target (p66Shc).Rota et al report in this issue of Circulation Research that the ablation of the p66shc gene prevents whole heart pathophysiological consequences of oxidative stress with streptozotocin (STZ)-induced diabetes in mice.10 Moreover the authors show that the unfavorable effects on cardiac stem/progenitor cells (CSCs), such as their numeric reduction and telomeric shortening (expression of cellular senescence), are not observed in the transgenic KO mice. Rota et al further demonstrate that exposure of high glucose to the isolated CSCs from diabetic WT, but not p66Shc−/−, induces the generation of ROS and apoptosis. A low or intermediate level of ROS causes proliferation of CSCs and a high level of ROS causes apoptosis or necrosis of CSCs.The recognition that p66Shc conditions the destiny of CSCs raises the possibility that diabetic cardiomyopathy is a stem cell disease, in which abnormalities in CSCs define the life and death of the heart. Rota et al, in fact, conclude that diabetic cardiomyopathy could be considered a "stem cell disease."Diabetes is a significant risk factor for cardiovascular morbidity and mortality, mainly through a procoagulant state and accelerated atherosclerosis leading to a coronaric disease. Moreover, diabetic cardiomyopathy is one of the common causes of heart failure, but the mechanism of the cardiac dysfunction is multifaceted and unclear. Interestingly, the protective effects of p66Shc ablation have been reported in EPCs as well,11 and many studies identify p66Shc as a critical transducer of oxidative stress signals. Thus the preserved cardiac function observed in the p66shc−/− mice could also reflect the general beneficial effect of the reduction of ROS production and action.Rota et al, however, focused on the consequences of hyperglycemia as a ROS-generating system that can participate in the activation of p66Shc in cardiac myocytes in general, and in cardiac stem cells in particular. It is in these cells, in fact, that the effects of the protein may achieve their more deleterious consequences in terms of senescence and apoptosis. The effective level and modulation of p66shc in cardiac stem cells, however, have not been studied in depth.Although p52Shc is detected in various cardiac cell preparations, p66Shc is readily detected in neonatal cardiomyocytes, but it is at the limits of detection in the adult ventricle. The expression of this protein is low and apparently ubiquitary in normal heart, but increases in a pacing model of heart failure in the dog, in association with an increase in cardiomyocyte apoptosis.12 The relative contribution of p66 to heart tissue damage in response to oxidative stress may reflect individual expression differences. Further studies should be performed to asses p66Shc levels in cardiac cells from diabetic patients.A recent study has identified a novel regulation of individual Shc isoforms in receptor-dependent pathways leading to cardiac hypertrophy and the transition to heart failure.7 The observation that p66Shc expression is induced by a Gαq agonist, and that PAR-1 activation leads to p66Shc-S36, identifies p66Shc as a novel candidate for a hypertrophy-induced mediator of cardiomyocyte apoptosis and heart failure. This same observation also confirms that p66Shc is an attractive novel molecular target for heart failure therapy.Some of the coauthors of Rota et al are the same investigators who first suggested the existence of cardiac myocytes renewal, and described for the first time the existence of a resident population of cardiac stem cells that, as in other organs, maintains the equilibrium between cell death and regeneration.13–14 In this view it is logical to attribute to CSC damage a "prima donna" role in the pathophysiology of diabetic cardiomyopaty.Other stem-progenitor cells (HSC, NCS, and EPC) have been described to be primarily involved in the pathophysiological sequelae of oxidative stress.11,15,16 However, this article by Rota et al represents the first time that CSC-specific damage has been recognized as a cause–effect mechanism specifically for cardiac disease. In the pathophysiology of diabetic cardiomyopathy in particular, and in heart failure in general, a strategic link has been introduced here between CSCs and p66Shc, a link that crosses between life span and senescence at cellular and molecular level. The article by Rota et al suggests that the level of p66Shc should be the critical factor for the preservation of equilibrium and vitality in cardiac cells. One consequence is that p66Shc levels or activation could inhibit maintenance of CSC quiescence, and affect the stemness function in vivo. Based on previously published data, and the data presented in this issue by Rota et al, it is reasonable to surmise that the ROS–p66Shc pathway may be involved in the pathophysiology of CSC senescence in normal aging, in hypertension, and in CSC exhaustion observed in diabetic mice. The characterization of the molecular mechanisms that limit CSCs lifespan may lead to beneficial therapies for human disease.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.DisclosuresNone.FootnotesCorrespondence to Dr Alessandro Giacomello, University of Rome "la Sapienza", Experimental Medicine and Pathology, viale Regina Elena 324, Rome 00161, Italy. E-mail [email protected] References 1 Ghafourifar P, Cadenas E. Mitochondrial nitric oxide synthase. Trends Pharmacol Sci. 2005; 26: 190–195.CrossrefMedlineGoogle Scholar2 Graiani G, Lagrasta C, Migliaccio E, Spillmann F, Meloni M, Madeddu P, Quaini F, Padura IM, Lanfrancone L, Pelicci PG, Emanueli C. Genetic deletion of the p66Shc adaptor protein protects from angiotensin II-induced myocardial damage. Hypertension. 2005; 46: 433–440.LinkGoogle Scholar3 Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, Pawson T, DiFiore PP, Lanfrancone L, Pelicci PG. Opposite effects of the p52shc/p46shc splicingisoforms on the EGF receptor-MAP kinase-fos signaling pathway. EMBO J. 1997; 16: 706–716.CrossrefMedlineGoogle Scholar4 Lotti LV, Lanfrancone L, Migliaccio E, Zompetta C, Pelicci G, Salcini AE, Falini B, Pelicci PG, Torrisi MR. Shc proteins are localized on endoplasmic reticulum membranes and are redistributed after tyrosine kinase receptor activation. Mol Cell Biol. 1996; 16: 1946–1954.CrossrefMedlineGoogle Scholar5 Costa LE, La-Padula P, Lores-Arnaiz S, D'Amico G, Boveris A, Kurnjek ML, Basso N. Long-term angiotensin II inhibition increases mitochondrial nitric oxide synthase and not antioxidant enzyme activities in rat heart. J Hypertens. 2002; 20: 2487–2494.CrossrefMedlineGoogle Scholar6 Purdom S, Chen QM. p66Shc: at the crossroad of oxidative stress and the genetics of aging. Trends Mol Med. 2003; 9: 206–210.CrossrefMedlineGoogle Scholar7 Obreztchikova M, Elouardighi H, Ho M, Wilson BA, Gertsberg Z, Steinbeg SF. Distinct signaling functions for SHC isoforms in the heart. J Biol Chem. In press.Google Scholar8 Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D, Martin-Padura I, Pelliccia G, Trinei M, Bono M, Puri C, Tacchetti C, Ferrini M, Mannucci R, Nicoletti I, Lanfrancone L, Giorgio M, Pelicci PG. The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential. J Biol Chem. 2004; 279: 25689–25695.CrossrefMedlineGoogle Scholar9 Zaccagnini G, Martelli F, Fasanaro P, Magenta A, Gaetano C, Di Carlo A, Biglioli P, Giorgio M, Martin-Padura I, Pelicci PG, Capogrossi MC. p66ShcA modulates tissue response to hindlimb ischemia. Circulation. 2004; 109: 2917–2923.LinkGoogle Scholar10 Rota M, LeCapitaine N, Hosoda T, Boni A, De Angelis A, Padin Iruegas E, Esposito G, Vitale S, Urbanek K, Casarsa C, Giorgio M, Lüscher TF, Pelicci PG, Anversa P, Leri A, Kajstura J. Diabetes promotes cardiac stem cell aging and heart failure which are prevented by deletion of the p66shc gene. Circ Res. 2006; 99: 42–52.LinkGoogle Scholar11 Callaghan MJ, Ceradini DJ, Gurtner GC. Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function. Antioxid Redox Signal. 7: 1476–1482.CrossrefMedlineGoogle Scholar12 Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal- Ginard B, Kajstura J, Leri A, Anversa P. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res. 2001; 89: 279–286.CrossrefMedlineGoogle Scholar13 Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114: 763–776.CrossrefMedlineGoogle Scholar14 Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: A paradigm shift in cardiac biology. Circulation. 2006; 113: 1451–1463.LinkGoogle Scholar15 Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, Ohmura M, Naka K, Hosokawa K, Ikeda Y, Suda T. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Medicine. 2006; 12: 446–451.CrossrefMedlineGoogle Scholar16 Madhavan L, Ourednik V, Ourednik J. Increased vigilance of antioxidant mechanisms in neural stem cells potentiates their capability to resist oxidative stress. Stem Cells. In press.Google Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Li J, Li J, Chen Y, Hu W, Gong X, Qiu H, Chen H, Xin Y, Li H and Li T (2022) The Role of Mitochondria in Metabolic Syndrome–Associated Cardiomyopathy, Oxidative Medicine and Cellular Longevity, 10.1155/2022/9196232, 2022, (1-17), Online publication date: 23-Jun-2022. Molinaro C, Salerno L, Marino F, Scalise M, Salerno N, Pagano L, De Angelis A, Cianflone E, Torella D and Urbanek K (2022) Unraveling and Targeting Myocardial Regeneration Deficit in Diabetes, Antioxidants, 10.3390/antiox11020208, 11:2, (208) Kaludercic N and Di Lisa F (2020) Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.00012, 7 Yi M, Li H, Wang X, Yan J, Gao L, He Y, Zhong X, Cai Y, Feng W, Wen Z, Wu C, Ou C, Chang J and Chen M (2018) Ion Therapy: A Novel Strategy for Acute Myocardial Infarction, Advanced Science, 10.1002/advs.201801260, 6:1, (1801260), Online publication date: 1-Jan-2019. Dergilev K, Zubkova E, Beloglazova I, Menshikov M and Parfyonova E (2018) Notch signal pathway - therapeutic target for regulation of reparative processes in the heart, Terapevticheskii arkhiv, 10.26442/00403660.2018.12.000014, 90:12, (112-121) Tomilov A, Allen S, Hui C, Bettaieb A and Cortopassi G (2018) Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition, Pharmacological Research, 10.1016/j.phrs.2018.09.024, 137, (89-103), Online publication date: 1-Nov-2018. Jankowski M, Broderick T and Gutkowska J (2016) Oxytocin and cardioprotection in diabetes and obesity, BMC Endocrine Disorders, 10.1186/s12902-016-0110-1, 16:1, Online publication date: 1-Dec-2016. Dong X, Zhang T, Liu Q, Zhu J, Zhao J, Li J, Sun B, Ding G, Hu X, Yang Z, Zhang Y and Li L (2016) Beneficial effects of urine-derived stem cells on fibrosis and apoptosis of myocardial, glomerular and bladder cells, Molecular and Cellular Endocrinology, 10.1016/j.mce.2016.03.001, 427, (21-32), Online publication date: 1-May-2016. Rodrigues M, Wong V, Rennert R, Davis C, Longaker M and Gurtner G (2015) Progenitor Cell Dysfunctions Underlie Some Diabetic Complications, The American Journal of Pathology, 10.1016/j.ajpath.2015.05.003, 185:10, (2607-2618), Online publication date: 1-Oct-2015. Roul D and Recchia F (2015) Metabolic Alterations Induce Oxidative Stress in Diabetic and Failing Hearts: Different Pathways, Same Outcome, Antioxidants & Redox Signaling, 10.1089/ars.2015.6311, 22:17, (1502-1514), Online publication date: 10-Jun-2015. Leonardini A and Avogaro A (2013) Abnormalities of the cardiac stem and progenitor cell compartment in experimental and human diabetes, Archives of Physiology and Biochemistry, 10.3109/13813455.2013.798334, 119:4, (179-187), Online publication date: 1-Oct-2013. Li Y, Yang C, Xi Y, Wu G, Shelat H, Gao S, Cheng J and Geng Y (2013) MicroRNA-1/133 targeted dysfunction of potassium channels KCNE1 and KCNQ1 in human cardiac progenitor cells with simulated hyperglycemia, International Journal of Cardiology, 10.1016/j.ijcard.2012.10.060, 167:3, (1076-1078), Online publication date: 1-Aug-2013. Diogo C, Suski J, Lebiedzinska M, Karkucinska-Wieckowska A, Wojtala A, Pronicki M, Duszynski J, Pinton P, Portincasa P, Oliveira P and Wieckowski M (2013) Cardiac mitochondrial dysfunction during hyperglycemia—The role of oxidative stress and p66Shc signaling, The International Journal of Biochemistry & Cell Biology, 10.1016/j.biocel.2012.07.004, 45:1, (114-122), Online publication date: 1-Jan-2013. Ashrafi R and Davis G (2011) Cardiomyopathy in diabetics: a review of current opinion on the underlying pathological mechanisms, Avances en Diabetología, 10.1016/j.avdiab.2011.08.002, 27:5, (175-181), Online publication date: 1-Sep-2011. Stilli D, Lagrasta C, Berni R, Bocchi L, Savi M, Delucchi F, Graiani G, Monica M, Maestri R, Baruffi S, Rossi S, Macchi E, Musso E and Quaini F (2007) Preservation of ventricular performance at early stages of diabetic cardiomyopathy involves changes in myocyte size, number and intercellular coupling, Basic Research in Cardiology, 10.1007/s00395-007-0665-0, 102:6, (488-499), Online publication date: 1-Nov-2007. July 7, 2006Vol 99, Issue 1 Advertisement Article InformationMetrics https://doi.org/10.1161/01.RES.0000233141.65522.3ePMID: 16825582 Originally publishedJuly 7, 2006 Keywordsdiabetesp66Shccardiac stem cellsPDF download Advertisement